A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.
Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as marine littering. The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead. The Commissions legislative proposal must then be negotiated with the member states and the European Parliament. And here substantial changes should still be made because so far industry and politics continued to fail in this area.
For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).
T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in over 30 years experience in the biopharmaceutical industry, with special expertise in strategic partnerships with Big Pharma. The Board member of the British Industry Organisation (BIA) is currently a non-executive director for cancer immunotherapy specialist Targovax ASA which recently announced new patents for its colon cancer RAS-targeting candidate drug TG02. Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV.
Three years ago Roche acquired a majority in shares of Foundation Medicines Inc (FMI), a specialist in cancer panel sequencing, which has build a huge database with cancer mutation profiles. Now Roche paid US2.4bn to complete the take-over.
Researchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA or S. pneumoniae effectively.
Following a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established work routines that are set to lower quality of European patents.
Adrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis.
Forbion, a European life science venture capital firm, today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.